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The habenula: an under-
recognised area of importance
in frontotemporal dementia?
INTRODUCTION
Behavioural variant frontotemporal
dementia (bvFTD) is a neurodegenerative
disorder characterised by atrophy of the
frontal and temporal lobes and progres-
sive behavioural and cognitive impair-
ment. Some behavioural symptoms such
as craving for food, alcohol or drugs,
and hypersexuality are suggestive of
abnormal reward processing. The reward
circuit is formed by a number of differ-
ent structures including the orbitofrontal
cortex, ventral striatum (in particular the
nucleus accumbens), ventral pallidum,
anterior cingulate cortex, thalamus,
hypothalamus, midbrain and habenula.1
This complex network combines infor-
mation about motivation, cognitive plan-
ning and motor control to develop an
appropriate goal-directed response to
external environmental stimuli. Many of
the brain structures belonging to the
reward circuit have been found to be
atrophic in bvFTD,2 supporting the
theory that impairment of the reward
system is an important factor in this
disease. Among these structures, the
habenula, found medial to the posterior
thalamus, is uniquely positioned to par-
ticipate in reward processing, acting as a
convergence point for the limbic system
and basal ganglia circuits,3 4 and there-
fore playing a pivotal role in the integra-
tion of information required to generate
goal-directed behaviours. Despite this
key role, it has yet to be investigated in
bvFTD.
The aim of this study was to investigate
the volume of the habenula in a cohort of
patients with bvFTD, hypothesising that it
would be smaller than in healthy controls
as well as an age-matched group of
patients with Alzheimer’s disease (AD)
who typically do not show impairment of
reward behaviour. We also hypothesised
that the habenula would show comparable
atrophy to other key areas in the reward
network in bvFTD.
METHODS
Fifteen participants fulﬁlling criteria for
the diagnosis of bvFTD (including eight
with a MAPT mutation and four with a
pathogenic expansion in the C9orf72
gene) were recruited consecutively from a
tertiary referral cognitive disorders clinic
at the National Hospital for Neurology
and Neurosurgery, London, UK. In total,
87% of the group were male with the
mean (SD) age at onset 55.3 (8.9) years
and disease duration 7.3 (3.8) years.
Fifteen participants fulﬁlling criteria for
typical AD (with early onset disease in
order to match for age) were also
recruited. Only 40% of the group were
male with the mean (SD) age at onset
54.9 (4.5) years and disease duration 5.9
(2.7) years. Fifteen healthy controls (47%
male) were also recruited. The mean (SD)
age at scan was 62.6 (9.8) in bvFTD, 60.7
(5.9) in AD and 61.4 (8.9) in the
controls, with no signiﬁcant differences
between the groups. Mini-Mental State
Examination differed between the groups,
being lowest in the AD group (20.4 (4.2))
then the bvFTD group (25.0 (4.6)) (AD vs
bvFTD, p=0.011), both being lower than
the control group (28.9 (1.3), p<0.001
and 0.055, respectively).
Segmentations of the habenula were
performed manually on coronal slices of a
volumetric T1-weighted MRI following a
novel segmentation protocol adapted
from previous descriptions5 6 (see online
supplementary data). We also calculated
volumes for the rest of the brain using a
cortical and subcortical parcellation as
previously described,7 (see online supple-
mentary data). All brain volumes were
corrected for total intracranial volume,
which was calculated using SPM12 (http://
www.ﬁl.ion.ucl.ac.uk/spm).
Statistical analyses were performed in
SPSS software V.22.0 (SPSS Inc, Chicago,
Illinois, USA). Differences in demographic
and cognitive features as well as
brain volumes were tested with the
Mann–Whitney U test for continuous
variables and χ2 test for dichotomous
variables. For the brain volumes (30 com-
parisons), the Bonferroni correction for
multiple comparisons was made so that
only a threshold of p≤0.001 was consid-
ered signiﬁcant.
RESULTS
The bvFTD group showed a 30% lower
right and a 28% lower left habenular
volume compared with controls (mean
(SD) right: 16.4 (2.7) vs 23.3 (2.2) mm3,
left: 16.9 (2.4) vs 23.6 (2.2), p<0.0005,
Mann-Whitney U test). The AD group
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was not signiﬁcantly different to controls
(<1% difference): mean (SD) right: 23.0
(2.9), left: 23.6 (3.1), but the bvFTD
group was signiﬁcantly smaller than AD
(right 29% and left 28% smaller,
p<0.0005 for both sides) (ﬁgure 1).
No other cortical or subcortical region
showed a larger percentage difference in
volume in bvFTD compared with controls
than the habenula (see online supplemen-
tary table). The insula cortex, amygdala,
hippocampus and nucleus accumbens were
the other most signiﬁcantly involved
regions, with volumes being 20% or smaller
than controls. Other areas of the reward
network including the frontal and cingulate
cortices, and thalamus showed smaller volu-
metric differences compared with controls
(see online supplementary table).
DISCUSSION
To the best of our knowledge, this is the
ﬁrst study investigating the habenula in
bvFTD. Compared with healthy controls
and patients with AD, bvFTD showed sig-
niﬁcantly smaller habenular volumes bilat-
erally. Furthermore, the habenula showed
the largest percentage difference in
volume in the bvFTD group compared
with controls out of all of the cortical and
subcortical regions measured. Similarly
affected regions included the nucleus
accumbens, amygdala, hippocampus and
insula cortex, which form part of the
reward network or are intrinsically linked
to it. Other key areas of the reward
network including the thalamus and
brainstem were affected to a lesser extent.
However, the key areas within the
network form smaller parts of the regions
measured in this study (ventral part of the
pallidum, dorsomedial nucleus of the thal-
amus and midbrain) and it may be that
subsegmentation of these regions would
show more speciﬁc involvement in these
particular subregions.
The habenula is involved in the process-
ing of aversive information. By inhibiting
dopamine-releasing neurones, it sup-
presses motor activity under adverse con-
ditions such as failure to obtain a reward
or anticipation of an unpleasant
outcome.8 For example, in a motion-
prediction fMRI task the habenula was
activated when a subject received feedback
indicating that their response was wrong.9
When the action of the habenula is
impaired (such as when it becomes atro-
phied), it is likely that even though the
outcome of an action may be negative, it
would be difﬁcult for a subject to avoid
the action. This may be expressed as
abnormal reward behaviours similar to
those seen in bvFTD including increased
impulsivity, binge eating and alcohol or
recreational drug abuse.
There are some limitations to this study.
Owing to the small dimensions of the
nucleus and the resolution of the MRI, it
was not possible to distinguish between
the lateral and medial habenula, and spe-
ciﬁcally locate the involvement within the
nucleus. The small sample size did not
allow us to further differentiate among
the different genetic mutations in FTD
and their potential different impact.
Moreover, we did not systematically
collect information about behaviours
linked to reward processing, preventing us
from investigating any possible correlation
with the clinical symptoms. Further
studies in larger genetic and pathologically
conﬁrmed cohorts are required to conﬁrm
the role of the habenula in bvFTD,
together with studies aimed at deﬁning
the functional and structural connections
of the habenula within the reward
network.
In summary, we found that in bvFTD
the region with the most atrophy in com-
parison to controls was the habenula and
that this region is uniquely affected in this
disorder in comparison with an age-
matched AD cohort. We suggest that the
habenula is an under-recognised area of
importance in bvFTD and may be a key
region involved in the development of
abnormal reward processing.
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Figure 1 Volume of the left and right habenula (corrected for total intracranial volume) in 15 patients with behavioural variant frontotemporal
dementia (bvFTD), 15 patients with Alzheimer’s disease (AD) and 15 controls: (A) by group and (B) comparing the right and left side.
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